ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber Sells 16,438 Shares

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 16,438 shares of ProKidney stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $2.51, for a total value of $41,259.38. Following the completion of the sale, the senior vice president now owns 155,194 shares of the company’s stock, valued at $389,536.94. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

ProKidney Stock Up 7.1 %

PROK stock opened at $2.71 on Thursday. ProKidney Corp. has a twelve month low of $1.12 and a twelve month high of $13.51. The stock has a market cap of $621.51 million, a P/E ratio of -4.75 and a beta of 1.08. The business’s 50-day moving average price is $1.66 and its 200-day moving average price is $1.72.

ProKidney (NASDAQ:PROK) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. On average, equities research analysts expect that ProKidney Corp. will post -0.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in shares of ProKidney during the 3rd quarter valued at about $78,000. Zullo Investment Group Inc. purchased a new position in shares of ProKidney during the 1st quarter valued at about $32,000. Jump Financial LLC purchased a new position in shares of ProKidney during the 3rd quarter valued at about $216,000. Finally, Federated Hermes Inc. lifted its position in shares of ProKidney by 10,984.7% during the 4th quarter. Federated Hermes Inc. now owns 113,286 shares of the company’s stock valued at $202,000 after buying an additional 112,264 shares in the last quarter. 51.59% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on PROK shares. Bank of America cut ProKidney from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Morgan Stanley started coverage on ProKidney in a research report on Thursday, March 7th. They issued an “equal weight” rating and a $3.00 target price on the stock.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.